StocktoriaAspire Biopharma Holdings, Inc. ASBP
Nasdaq · XNAS · stock · Pharmaceutical Preparations
Chart by TradingView
3/9
Piotroski F — financial health
—
Altman Z″ — distress risk
—
Dividend payout · no dividend
Financials & ratios (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Financials | ||||
| Revenue | $6,202 | — | — | — |
| Gross profit | -$116 | — | — | — |
| Operating income | -$19.4M | -$1.2M | — | — |
| Net income | -$24.5M | -$1.3M | $4.5M | $3.3M |
| Operating cash flow | -$4.9M | -$265,186 | -$653,107 | -$1.4M |
| Total assets | $1.3M | $147,989 | $20.0M | $300.2M |
| Total liabilities | $7.7M | $1.7M | $403,328 | $11.1M |
| Shareholders' equity | -$6.4M | -$1.5M | -$487,861 | -$9.9M |
| Ratios | ||||
| Gross margin | -1.9% | — | — | — |
| Operating margin | -312016.9% | — | — | — |
| Net margin | -394725.1% | — | — | — |
| Return on assets | -1865.7% | -885.1% | 22.3% | 1.1% |
| Return on equity | 383.9% | 85.1% | -915.0% | -33.6% |
| Current ratio | 0.17 | 0.09 | 0.20 | 3.62 |
Why these scores methodology →
Piotroski F-score: 3/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: n/a
Not applicable (financials/insurer or missing inputs).
Sector peers
VFS · TM · HMC · SONY · AAPL · XOM · all Manufacturing →
Source: SEC EDGAR filings · CIK 0001847345 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.